Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04617275 · ClinicalTrials.gov registry record · Phase 2
A 12-week Titrate Study TO Evaluate Safety, Tolerability AND Pharmacodynamics OF PF-06882961 IN Adults With Type 2 Diabetes Mellitus AND IN Non-diabetic Adults With Obesity
A Phase 2 study of Obesity and Diabetes, sponsored by Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 151
- Enrollment target
- 20
- Study locations
NCT04617275 is a Phase 2 study of Obesity and Diabetes that has completed, run by Pfizer. The registered enrollment target is 151 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT04617275, a Phase 2 study of Obesity and Diabetes, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 151 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in non-diabetic adults with obesity
Interventions
- OTHER Placebo
- DRUG PF-06882961
Study Locations (20)
California
- Catalina Research Institute, LLC - Montclair
- Desert Oasis Healthcare Medical Group - Palm Springs
- Rancho Cucamonga Clinical Research - Rancho Cucamonga
- California Research Foundation - San Diego
- University Clinical Investigators, Inc. - Tustin
- Diablo Clinical Research, Inc. - Walnut Creek
Florida
- Innovative Research of West Florida, Inc. - Clearwater
- Clinical Neuroscience Solutions, Inc. - Jacksonville
- Acevedo Clinical Research Associates - Miami
- Pines Care Research Center, LLC - Pembroke Pines
Arizona
- Arizona Research Center - Phoenix
Arkansas
- Unity Health - Searcy Medical Center - Searcy
District of Columbia
- Emerson Clinical Research Institute - Washington D.C.
Idaho
- Solaris Clinical Research - Meridian
Iowa
- Meridian Clinical Research, LLC - Sioux City
Kentucky
- Research Integrity, LLC - Owensboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2021-01-06 |
| Est. Completion | 2021-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04617275
The ClinicalTrials.gov registry entry for NCT04617275 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (82% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04617275 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04617275 about?
NCT04617275 is a clinical study titled "A 12-week Titrate Study TO Evaluate Safety, Tolerability AND Pharmacodynamics OF PF-06882961 IN Adults With Type 2 Diabetes Mellitus AND IN Non-diabetic Adults With Obesity". This study will assess tolerability, safety, and pharmacodynamics (PD) of twice daily (BID) administration of PF- 06882961 in adult participants with Type 2 Diabetes Mellitus (T2DM) who are treated with metformin and in non-diabetic adults with obesity
What is the current status of trial NCT04617275?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 151 participants. The study started on 2021-01-06. Estimated completion is 2021-11-17.
What conditions does trial NCT04617275 study?
This clinical trial studies the following conditions: Obesity, Diabetes.
What interventions are being tested in trial NCT04617275?
The interventions under investigation include: Placebo (OTHER), PF-06882961 (DRUG).
Who is sponsoring clinical trial NCT04617275?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04617275 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.